Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the ...
Aeolus Pharmaceuticals reported revenue of $2.08 million for fiscal year 2016, down 33.3% from fiscal year 2015, and net income of -$6.04 million. In Q3 2017 (the quarter ended June 30, 2017) revenue was $13,000, down 98.0% from a year before.
Figures from company filings; latest fiscal year ended September 30, 2016.
No profile data available.